U.S.: China De Minimis Gone + New Tariffs
- Arne Mielken
- Apr 27
- 6 min read
This April 2025 US Executive Order further targets synthetic opioid imports from China, suspending de minimis duty exemptions and imposing new tariffs.

The Executive Order issued on April 2, 2025, addresses the issue of synthetic opioids being shipped from the People's Republic of China (PRC) and Hong Kong to the United States through deceptive shipping practices, often utilizing the de minimis exemption under section 321(a)(2)(C) of the Tariff Act of 1930.
The order introduces further amendments to duties related to these imports in light of the ongoing synthetic opioid crisis.
Questions We Answer In This Blog:
What is the suspension of duty-free de minimis treatment?
How will low-value products from the PRC and Hong Kong be impacted?
What changes will apply to postal shipments from the PRC and Hong Kong?
What are the carrier requirements under this new order?
Is there a bond requirement for carriers?
When can CBP require formal entry?
How will the implementation and monitoring of this order work?
What does the temporary suspension of the parenthetical exception in 19 CFR 143.21(a) mean for all countries and modes of entry, effective April 30, 2025?
Can informal entries still be made for goods up to $2,500 in value?
What does the temporary suspension of 19 CFR 145.12(b) mean for mail shipments from China or Hong Kong?
Will formal entry now be required for mail shipments valued over $800?
What should trade filers know about de minimis clearance for affected goods arriving on or after May 2, 2025?
Why are shipments likely to be rejected if de minimis clearance is requested?
What detailed guidance is available for carriers handling international mail from China or Hong Kong?
Want to read more?
Subscribe to customsmanager.info to keep reading this exclusive post.